Title:
MEDICINE FOR TREATING OR PREVENTING CANCER
Document Type and Number:
WIPO Patent Application WO/2023/140329
Kind Code:
A1
Abstract:
A medicine for treating or preventing cancer, the medicine comprising a first active ingredient used together with a second active ingredient, the first active ingredient being a compound expressed by formula (1) or a salt thereof or a solvate of same, the second active ingredient being a molecular targeting agent.
More Like This:
| JPS53132588 | SOMATOSTATINE HOMOLOGUE AND SYNTHETIC INTERMEDIATE THEREOF |
| JP6592097 | Combination therapy |
| WO/2005/019241 | CATIONIC ANTIMICROBIAL PEPTIDES AND COMPOSITIONS THEREOF |
Inventors:
SASE HITOSHI (JP)
HIRANO SAKI (JP)
HIRANO SAKI (JP)
Application Number:
PCT/JP2023/001552
Publication Date:
July 27, 2023
Filing Date:
January 19, 2023
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K38/12; A61K31/4184; A61K31/44; A61K31/47; A61K31/497; A61K31/506; A61K31/517; A61K31/519; A61K31/5377; A61K39/395; A61K45/00; A61P35/00; A61P35/02; A61P43/00; C07K7/02; C07K16/28
Domestic Patent References:
| WO2021090855A1 | 2021-05-14 | |||
| WO2020165732A1 | 2020-08-20 | |||
| WO2020205473A1 | 2020-10-08 |
Foreign References:
| JP2020105162A | 2020-07-09 |
Other References:
HABIB ZARREDAR; SHADI PASHAPOUR; KHALIL ANSARIN; MAJID KHALILI; ROGHAYYEH BAGHBAN; SAFAR FARAJNIA: "Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY SUBSCRIPTION SERVICES, INC., US, vol. 234, no. 2, 21 August 2018 (2018-08-21), US , pages 1560 - 1566, XP071310173, ISSN: 0021-9541, DOI: 10.1002/jcp.27021
TABERNERO J., BENDELL J., CORCORAN R., KOPETZ S., LEE J., DAVIS M., CHRISTENSEN J., CHI A., KHEOH T., YAEGER R.: "P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation", ANNALS OF ONCOLOGY, vol. 32, 1 July 2021 (2021-07-01), pages S121, XP093079447, ISSN: 0923-7534, DOI: 10.1016/j.annonc.2021.05.126
LIU CHEN; LU HENGYU; WANG HONGYUN; LOO ALICE; ZHANG XIAMEI; YANG GUIZHI; KOWAL COLLEEN; DELACH SCOTT; WANG YE; GOLDONI SILVIA; HAS: "Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 27, no. 1, 1 January 2021 (2021-01-01), US, pages 342 - 354, XP009528840, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-20-2718
SMITH, JACQUELINE A. ET AL.: "Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 80, no. 16, 1 January 2020 (2020-01-01), US, pages 1 - 4, XP009547471, ISSN: 1078-0432, DOI: 10.1158/1538-7445.AM2020-1943
TABERNERO J., BENDELL J., CORCORAN R., KOPETZ S., LEE J., DAVIS M., CHRISTENSEN J., CHI A., KHEOH T., YAEGER R.: "P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation", ANNALS OF ONCOLOGY, vol. 32, 1 July 2021 (2021-07-01), pages S121, XP093079447, ISSN: 0923-7534, DOI: 10.1016/j.annonc.2021.05.126
LIU CHEN; LU HENGYU; WANG HONGYUN; LOO ALICE; ZHANG XIAMEI; YANG GUIZHI; KOWAL COLLEEN; DELACH SCOTT; WANG YE; GOLDONI SILVIA; HAS: "Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 27, no. 1, 1 January 2021 (2021-01-01), US, pages 342 - 354, XP009528840, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-20-2718
SMITH, JACQUELINE A. ET AL.: "Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 80, no. 16, 1 January 2020 (2020-01-01), US, pages 1 - 4, XP009547471, ISSN: 1078-0432, DOI: 10.1158/1538-7445.AM2020-1943
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF: